Idiopathic Pulmonary Fibrosis Clinical Trial Using Placebo and FG-3019

- The folks at FibroGen are studying the effects of FG-3019; Placebo on Idiopathic Pulmonary Fibrosis in individuals ages 40 years to 80 years. This clinical trial is slated to start June 2013 and is expected to end circa November 2016.

415-978-1455
John L. Stauffer, M.D
Overall Study Contact Info
StatusName Contact Phone
RecruitingJohn L. Stauffer, M.Djstauffer@fibrogen.com415-978-1455

This study is officially titled, "A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of FG-3019 in Patients With Idiopathic Pulmonary Fibrosis."

Locations

Robert Wood Johnson Medical School

Brunswick, New Jersey - Recruiting

St. Luke's Hospital

Chesterfield, Missouri - Recruiting

Steward St. Elizabeth's Medical Center

Boston, Massachusetts - Recruiting

University of Louisville

Louisville, Kentucky - Recruiting

Via Christi Clinic, P.A.

Wichita, Kansas - Recruiting

Northwestern University

Chicago, Illinois - Recruiting

Emory University

Atlanta, Georgia - Recruiting

Central Florida Pulmonary Group, PA

Orlando, Florida - Recruiting

Yale University

New Haven, Connecticut - Recruiting

UC Davis Medical Center

Sacramento, California - Recruiting

The Kirklin Clinic

Birmingham, Alabama - Recruiting

University of Cinncinati

Cincinnati, Ohio - Recruiting

The Ohio State University

Columbus, Ohio - Recruiting

University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania - Recruiting

Vermont Lung Center

Colchester, Vermont - Recruiting

For more study details, please visit this link to ClinicalTrials.gov record, which is the source of this webpage.